Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?

Hologic (HOLX) reported strong Q3 FY25 results, with revenues of $1.02 billion and EPS of $1.08, both surpassing estimates, driven by robust performance in its Diagnostics and Surgical segments. Consequently, the company raised its full-year 2025 revenue guidance to $4.08-$4.09 billion and non-GAAP EPS to $4.23-$4.26, citing the strong quarter and successful tariff mitigation efforts. Despite a year-over-year dip in Breast Health revenues, sequential improvement and planned AI innovation signal a rebound, supported by a strong balance sheet and strategic initiatives. While Hologic continues to navigate macroeconomic volatility and persistent tariff costs, particularly in China, its solid financial position and diversified growth drivers position it for continued performance.

Analysis

Hologic (HOLX) delivered a strong third-quarter fiscal 2025 performance, exceeding consensus estimates with revenue of $1.02 billion and an adjusted EPS of $1.08. This beat was driven by significant strength in its Surgical and Skeletal Health divisions, which saw revenue growth of 24.8% internationally and 62.1% respectively, the latter benefiting from the resolution of a shipping hold. While the core Diagnostics segment posted modest 0.9% growth, U.S. Molecular Diagnostics was a bright spot with a 7.3% sales increase. The key Breast Health division, despite a 5.8% year-over-year revenue decline against a tough comparison, showed sequential improvement and surpassed internal expectations, signaling a potential turnaround under new leadership and ahead of the 2026 launch of its Genius AI Detection PRO solution. In response to the strong quarter and successful mitigation of tariff impacts, Hologic raised its full-year 2025 guidance for revenue to $4.08-$4.09 billion and EPS to $4.23-$4.26. However, headwinds persist; the company still anticipates $10-$12 million in quarterly tariff costs in fiscal 2026, and margin pressure was evident with gross and operating margins declining 80 bps and 110 bps, respectively. The company's valuation presents a mixed picture, trading at a 3.55x forward price-to-sales ratio, which is a discount to the industry but a premium to peers GEHC and BDX.

Key Decisions for Investors

• Given the earnings beat, raised guidance, and early signs of a rebound in the Breast Health segment, current investors could consider holding their positions to monitor the execution of the recovery strategy and AI product pipeline.
• Prospective investors should weigh the company's operational strengths and discounted industry valuation against persistent tariff costs and specific international weaknesses, such as in China, before establishing a new position.
• Monitor the sequential revenue trajectory of the Breast Health division and the company's ability to defend its projected low-30s operating margin as key performance indicators for the coming quarters.
• Evaluate Hologic's premium valuation relative to peers Becton Dickinson (BDX) and GE Healthcare (GEHC) in the context of its strong balance sheet, low leverage, and growth drivers in niche segments like GYN Surgical and diagnostics.